| Age yrs | 50±14 |
| Females | 95 (74) |
| Ethnicity | |
| White, non-Hispanic | 80 (63) |
| Black | 9 (7) |
| Hispanic | 19 (15) |
| Asian | 14 (11) |
| Other | 6 (5) |
| Aetiology of pulmonary hypertension | |
| Idiopathic PAH | 50 (39) |
| Associated PAH | |
| Connective tissue disease | 36 (28) |
| Congenital heart disease | 3 (2) |
| Portal hypertension | 16 (13) |
| HIV | 6 (5) |
| Drug- and toxin-induced | 11 (9) |
| Other | 6 (5) |
| Right heart catheterisation | |
| Mean right atrial pressure# mmHg | 11±8 |
| Mean pulmonary artery pressure mmHg | 50±13 |
| Mean pulmonary capillary wedge pressure mmHg | 9.8±4.0 |
| Cardiac index# L·min−1·m−2 | 2.4±0.9 |
| Pulmonary vascular resistance# dyne·s·cm−5 | 886±464 |
| WHO functional class | |
| I | 8 (6) |
| II | 45 (35) |
| III | 66 (52) |
| IV | 9 (7) |
| 6-minute walk test¶ | |
| 6MWD m | 348±115 |
| BDI post-walk | 2.7±2.0 |
| Medications | |
| Intravenous or subcutaneous prostacyclin infusion | 49 (38) |
| Inhaled prostacyclin | 4 (3) |
| Oral endothelin receptor antagonist | 82 (64) |
| Oral phosphodiesterase-5 inhibitor | 41 (32) |
Data are presented as mean±sd or n (%). WHO: World Health Organization; 6MWD: 6-min walking distance; BDI: Borg dyspnoea index. #: data missing for seven subjects; ¶: data missing for three subjects.